Review of experimental attempts of islet allotransplantation in rodents: Parameters involved and viability of the procedure

Table 1 Description of the experimental studies on allografts in rodents

Ref.	Donor/recipient	Immunosuppression	Allotransplantation site	Graft survival time
Fotiadis et al[9]	Lewis→ Wistar	Mycophenolate mofetil (MMF) and Cyclosporine A (CsA)	Spleen	N/A
Merani et al[10]	Lewis →Wistar	AEB-071 (Protein kinase C inhibitor) + CsA, CTLA4-Ig, MMF	Kidney capsule	100 d
Nishimura et al[11]	C57BL/6 → Balb/c	Tacrolimus	Nonmetallic dorsal skinfold chamber	N/A
Makhlouf et al[12]	C57BL/6/Balb/c	Blockade of CD28:B7 and anti-CD40L; CTLA-4	Kidney capsule	1 wk
Salazar-Bañuelos et al[13]	Wistar →Sprague Dawley	No immunosuppression	Medullary channel	21 d
Wee et al[14]	Lewis → Fisher	CsA + Tautomycetin (synergist)	Liver (portal vein)	Control group - 5.2 ± 0.5 d TMC - 5.1 ± 0.9 d TMC (0.03 mg/kg) + CsA (5 mg/kg) - > 41 d TMC (0.1 mg/kg) + CsA (5 mg/kg) - 103.8 ± 56.8 d
Plesner et al[15]	Balb/c →EBA	No immunosuppression	Kidney capsule	60 d
Watanabe et al[16]	Balb/c → C57BL/6	Tacrolimus and DHMEQ (NF-κB inhibitor)	Kidney capsule	100 d
Gysemans et al[17]	Balb/c→ C57BL/6	No immunosuppression	Kidney capsule	9.2 ± 4.9 d (Autoimmune diabetes) 15 ± 3 d (Not chemically diabetic autoimmune)
Xekouki et al[18]	Wistar→Lewis	CsA and MMF	Spleen (parenchyma)	8 d (CsA) 10.92 d (MMF 1) 11 d (MMF 2)
Baker et al[19]	A/J→ C57Bl/6J	Monoclonal antibody antiBIP-10	Kidney capsule	19.7 ± 2.3 d (C57Bl/6J) 20.2 ± 2.7 d (CXCR3-/-C57Bl/6J
Li et al[20]	FVB→ Balb/c	No immunosuppression	Kidney capsule	N/A
Vieiro et al[21]	C57Bl/6→ C3H	Tritiated thymidine (preoperative) and CsA	Subcutaneous	N/A
Neuzillet et al[22]	C3H → Balb/c	No immunosuppression	Kidney capsule	13.8-27.5 d
Melzi et al[23]	C57Bl/6 → Balb/c	Rapamycin+ FK506+ anti-IL- 2Ra chain mAbs and rapamycin+IL-10	Kidney capsule	> 100 d
Fiorina et al[24]	Balb/c→ C57Bl/6	No immunosuppression	Kidney capsule	14 d
Fan et al[25]	C57Bl/6 → Balb/c	LTß R-Ig, CTLA4-Ig or LTR mAb anti mouse		LTβ R-Ig- 27 d CTLA4-Ig- 55 d LTβ R-Ig+CTLA4-Ig - > 100 d LTR mAb anti mouse - 11 d
Jung et al[26]	Balb/c → C57Bl/6	CD154 mAb (MR1) anti mouse and ROS-A (Reactive Oxygen Specie - A)	Kidney capsule	ROS-A - 53 d MR1 - 82 d ROS-A+MR1 - > 160 d
Påhlman et al[27]	Balb/c → C57Bl/6J	AR-C117977 (10 or 30 mg/kg) or CsA 20 mg/kg	Kidney capsule	CsA - 16 d AR-C117977, 10 mg/kg - >100 d AR-C117977, 30 mg/kg -29,33 d
Wang et al[28]	Balb/c → C57Bl/6	B7-H4 and Ad-LacZ	Kidney capsule	B7-H4 - approximately 60 d Ad-LacZ - approximately > 20 d
Chen et al[29]	Sprague Dawley → Lewis	No immunosuppression	Intra-abdominal	8 wk
Giraud et al[30]	C3H → Balb/c	No immunosuppression	Kidney capsule	SCOT + PEG 20 kDa ³10 g/L - 20 d, CMRL-1066 + 1% BSA - 17.5 ± 1 d, Solution UW - 17.2 ± 0.4 d, SCOT without PEG - 14 ± 0.9 d Solution HBSS + 0.5% BSA - 14 ± 0.7 d
Qi et al[31]	Wistar/Lewis → Lewis	No immunosuppression	Intraperitoneal (Macroencapsulated) Kidney capsule (not macroencapsulated)	24 wk (Macroencapsulated) 48 h (not macroencapsulated)
Potiron et al[32]	Wistar → C57Bl/6	CTLA4 Ig or CD40 Ig	Kidney capsule	24.3 ± 9.7 d
Jahr et al[33]	Lewis → Wistar	Anti-rat antilymphocyte serum	Liver (portal vein)

N/A: Not available.